Skip to content
Clinical Trials – home

ASL Napoli 2 Nord - Ospedale Santa Maria delle Grazie

Verifiedinfo

Italy Via domitiana, 80078 Pozzuoli, Italy

  • 7 trials recruiting
  • Colorectal cancer metastatic · Triple negative breast cancer · Metastatic renal cell carcinoma
  • Adult patients

About Specializations

ASL Napoli 2 Nord - Ospedale Santa Maria delle Grazie in Pozzuoli, Italy specialises in clinical trials of conditions such as Colorectal cancer metastatic, Triple negative breast cancer, Metastatic renal cell carcinoma, Breast cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, with a particular focus on innovative treatment strategies for bladder cancer. The center is exploring the potential of combining immunotherapy agents such as Durvalumab and Tremelimumab with Enfortumab Vedotin to enhance therapeutic outcomes for patients who are ineligible for traditional treatments like cisplatin.

  • Immunotherapy Combinations
  • Advanced Bladder Cancer Treatments
  • Non-Cisplatin Therapies

Through rigorous clinical trials, the center aims to improve the safety and efficacy of these novel combinations, offering new hope to patients with limited treatment options.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via domitiana80078 PozzuoliItaly
Recruiting now
7 trials
Conditions studied
8
Partner status
Verified

More sites in PozzuoliItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

10 clinical trials

Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Consorzio Oncotech
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Consorzio Oncotech
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:Consorzio Oncotech
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.